Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06334601
Recruiting Observational

Diurnal Evaluation of OSA Upper Airway Collapsibility and Muscle Responsiveness

NCT06334601 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Auxologico Italiano
Phase
Observational
Started
2023-01-15
Last updated
2025-04-30

Condition(s) studied

Obstructive Sleep Apnea

Investigational drug(s) / intervention(s)

Tests of upper airway collapsibility and muscle responsiveness.

Tests of upper airway collapsibility and muscle responsiveness.: Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit. Polysomnography

Study summary

In the framework of pathophysiological trait in obstructive sleep apnea (OSA) patients, a simplified method is proposed to measure upper airway (UA) collapsibility and muscle responsiveness during wakefulness.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Obstructive Sleep Apnea (OSA) * At home-polygraphy with at least one EEG channel (PSG) reporting moderate-to severe obstructive sleep apnea (apnea-hypopnea index \>14). Exclusion Criteria: * OSA treatment ongoing during two weeks before PSG * Unstable cardio-respiratory disease in the 3 months before enrollment * Subjects in O2 treatment

Primary outcome measure(s)

  • Upper airway collapsibility — During the diagnostic test
    Evaluation during wakefulness
  • Upper airway muscle responsiveness — During the diagnostic test
    Evaluation during wakefulness

Trial sites (1)

FacilityCityRegionStatus
IRCCS Istituto Auxologico Italiano,Ospedale San Luca Milan Italy Recruiting

More Istituto Auxologico Italiano trials in Italy

Implantable Loop Recorder and Cardioneuroblation Starting soon
Vesiculogenesis in Children With GH Deficiency (VESCIGHTP) Active, not recruiting
Exploring the Full Body Representation in Anorexia Nervosa and Bulimia Nervosa Recruiting
Impact of WBC on Patients With Metabolic or Neurological Diseases or Fibromyalgia (WBC-MeNeFi) Recruiting
The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study Recruiting

Other trials for the same condition

Brain Fog in Sleep Apnea Recruiting
Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy Recruiting
Effort-based Decision-making and CPAP Adherence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06334601 on ClinicalTrials.gov ↗ ← All trials in Italy